Jodie Morrison

Jodie Morrison is acting Chief Executive Officer of Q32 Bio, bringing biopharma leadership experience from start up through mid-size public biotech and pharmaceutical companies. Jodie is a venture partner at Atlas Venture and was CEO of Cadent Therapeutics until its sale to Novartis in 2020. Previous roles include serving as interim CEO at Keryx Biopharmaceuticals, Inc. (at the time of the merger with Akebia), acting Chief Operating Officer at Syntimmune (acquired by Alexion), and President and CEO of Tokai Pharmaceuticals, where she oversaw the company’s successful initial public offering. Prior to being appointed President and Chief Executive Officer at Tokai Pharmaceuticals, Jodie held other senior positions with the company, including Chief Operating Officer, Head of Clinical Affairs and Program Operations, and Vice President of Clinical Affairs and Program Operations. Prior, Jodie held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc.

Jodie holds a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from Boston University School of Medicine and received her business training through the Greater Boston Executive Program at the MIT Sloan School of Management. She currently sits as Chair of the Board of Directors for Ribon Therapeutics, Inc., and as a member of the Board of Directors at Rectify Pharmaceuticals, Inc. and Aileron Therapeutics, Inc.